Moreau Pierre, Schiffrin Ernesto L
Laboratory of Vascular Pharmacology, Faculty of Pharmacy, Université de Montréal, PO Box 6128, Succ. Centre-ville, Montréal, QC H3C 3J7, Canada.
Can J Physiol Pharmacol. 2003 Jun;81(6):511-21. doi: 10.1139/y03-015.
Investigation of the regulation of vascular function by endothelium-derived factors has been a prominent topic of research in the field of hypertension during the last decade. Of the different endothelial factors, endothelins, which play an important role in vasodilatation-vasoconstriction balance, have been the subject of great interest and an impressive number of publications. This peptide, a very potent vasoconstrictor, triggers as well events involved in growth, proliferation, matrix production and local inflammation. In parallel, its role in hypertension has evolved from a simple vasoconstrictor to a central local regulator of vascular homeostasis contributing not only to the elevation of blood pressure, but also to the complications of hypertension. This review summarizes research on endothelins and its receptor antagonists in experimental hypertension, with special emphasis on vascular remodeling and target-organ protection.
在过去十年中，内皮衍生因子对血管功能的调节研究一直是高血压领域的一个突出研究课题。在不同的内皮因子中，内皮素在血管舒张 - 血管收缩平衡中起重要作用，一直是人们非常感兴趣的主题，并且有大量的相关出版物。这种肽是一种非常有效的血管收缩剂，还会引发与生长、增殖、基质产生和局部炎症有关的事件。与此同时，它在高血压中的作用已从简单的血管收缩剂演变为血管稳态的核心局部调节因子，不仅导致血压升高，还会引发高血压并发症。这篇综述总结了实验性高血压中内皮素及其受体拮抗剂的研究，特别强调了血管重塑和靶器官保护。
